Register to watch this free webinar on-demand. A link to watch the recording will then be emailed to you shortly after registration.
Showcasing how MEG can be used in drug discovery and evaluation work & could support in drug development trials.* Hosted by MEGIN and Krish Singh, PhD at Campus Biotech, Geneva.
00:00:26 - Opening remarks by H.E. Ms. Heidi Schroderus-Fox, Ambassador, Permanent Representative of Finland to the UN and international organizations in Geneva
and Professor Krish Singh, PhD
00:06:26 - Krish Singh, PhD: MEG-derived non-invasive markers of oscillatory activity and connectivity in human drug target engagement studies
Professor, Head of Human Electrophysiology, Cardiff University Brain Research Imaging Centre (CUBRIC)
00:42:10 - Neil Harrison, PhD MRCP MRC Psych: The crisis in psychiatry drug discovery: can in-vivo target engagement measures save us?
Clinical Professor in Neuroimaging, Cardiff University Brain Research Imaging Centre (CUBRIC)
01:06:03 - Emily Rogers, PhD: MEG Beyond Academia: How Can We Best Leverage and Expand MEG To Address Unmet Needs in Industry
Medical Science Liaison, Neuralis
01:31:45 - Christos Papadelis, PhD: Electrophysiological Biomarkers of GABA in Children with Dravet Syndrome
Director of Neuroscience Research, Cook Children's Health Care, Professor of Pediatrics, Texas Christian University School of Medicine
01:56:32 - Hanna Renvall, PhD: Time-resolved tracking of neuronal activity combined with artificial intelligence: Tools for predicting dementia risk
Head of the MEG Lab at BioMag Laboratory at Helsinki University Hospital
Assistant Professor in Translational Neuroimaging, Aalto University and Helsinki University Hospital
02:22:17 - Laura Hughes, PhD: MEG: Sensitivity to pharmaco modulation in health and in dementia
Postdoctoral Fellow, MRC Cognition and Brain Sciences Unit, University of Cambridge
02:48:42 - Srikantan Nagarajan, PhD: Neurophysiological network alterations and trajectories in dementia
Professor, Director of Neuroimaging, Director, Biomagnetic Imaging Lab, UCSF
03:26:11 - Elizabeth Davenport, PhD: Tau Delta: The Unlikely Fraternity of Pediatric Football Players and Alzheimer’s Patients
Assistant Professor of Radiology
Technical Director for the Magnetoencephalography Center of UT Southwestern Medical Center
03:52:15 - Giulio Pergola, PhD: All roads lead to Schizophrenia: parsing risk into biological pathways
Associate Professor of Cognitive Neuroscience and Biological Psychology, Scientific Director - Group of Psychiatric Neuroscience, University of Bari Aldo Moro
Investigator, Lieber Institute for Brain Development
Associate Professor of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine
04:20:06 - James Rowe, PhD, MD: MEG markers of Alzheimer’s disease, severity and progression
Professor of Cognitive Neurology, University of Cambridge
04:50:39 - Olivier Reynaud, Campus Biotech MEG lab
04:56:29 - Alexis Hervais-Adelman, NCCR Evolving language
05:06:29 - Closing remarks from MEGIN
*MEGIN does not endorse any applications or treatments mentioned at this event. TRIUX neo™ is intended for use as a magnetoencephalographic (MEG) device that non-invasively detects and displays biomagnetic signals produced by electrically active nerve tissue in the brain. When interpreted by a trained clinician, the data enhances the diagnostic capability by providing useful information about the location relative to the brain anatomy of active nerve tissue responsible for critical brain functions. All other applications are investigational
*By submitting your information to register for a Masterclass, MEGIN will use it to communicate with you regarding this event and other services.